ASH® 2025 Highlights: Presenter Vignette – Romain Guieze
Romain Guieze
MD, PhD
CHU Clermont-Ferrand
684
Time-limited acalabrutinib monotherapy in frail patients with previously untreated chronic lymphocytic leukemia: Primary endpoint analysis of the randomized STAIR trial.
This program has been made possible through unrestricted support from Astellas, Daiichi Sankyo, Eli Lilly and Merck.
